CClinicalTrials.gg
CompletedNCT00225693ELUTES IIIUpdated Feb 1, 2012

V-Flex Plus PTX Drug Eluting Coronary Stent

An interventional study of drug eluting coronary stent in Coronary Artery Disease, sponsored by Cook Group Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-01.

Sponsored by Cook Group Incorporated · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is intended to collect data to evaluate effectiveness and safety of drug eluting stent devices in a dose ranging assessment.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • coronary artery
  • restenosis
  • patency
  • drug eluting
  • stent
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 150 is above the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Cook Group Incorporated is the lead sponsor of 73 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery.
  • Patient must be an acceptable candidate for coronary artery bypass surgery
  • Patient or legal guardian must have given informed consent
  • Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status, an IVUS examination and a diagnostic angiogram.

Exclusion criteria

Exclusion Criteria:

  • Patient must be less than 18 years old
  • Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  • Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study.
  • Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye.
  • Women of child bearing potential.
  • Patient has other medical condition that any cause non-compliance with the protocol, confound the results or is associated with limited life expectancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants

Interventions

  • Devicedrug eluting coronary stent
06

What researchers measure

Primary outcomes

  1. Evaluation by IVUS of % diameter stenosis at follow up.

Secondary outcomes

  1. Major adverse events

  2. Target lesion revascularization

07

Study locations

1 site
  • Contact Sponsor
    Bloomington, Indiana, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00225693
Lead sponsor
Cook Group Incorporated
First posted
Sep 26, 2005
Start date
Oct 2003
Completion
Jul 2005
Last update
Feb 1, 2012

Study contacts

Joseph Dens, MD
principal investigator · UZ Gasthuisberg Leuven
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion